ACCESSWIRE
24 Feb 2021, 18:13 GMT+10
VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ('XPhyto' or the 'Company'), is pleased to announce that it has placed the first order for its rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ('Covid-ID Lab') from its exclusive diagnostic development partner, 3a-diagnostics GmbH ('3a').
The first order of Covid-ID Lab is for 9,600 individual tests, which are packaged in 200 kits of 48 tests each. Delivery of the first order is expected by mid-March 2021 and will be primarily used to supply prospective distribution partners and licensees and their respective government regulators with test samples for review and evaluation. The tests will be manufactured in the German state of Baden-Württemberg.
'We are pleased to report that all steps towards the launch of Covid-ID Lab remain on track within an ambitious timeline,' said Hugh Rogers, CEO, and Director of XPhyto. 'Our experienced market launch team is working quickly to bring the product to market, as well as to establish licensing and distribution partnerships. We are confident that Covid-ID Lab, as a 25-minute PCR test with minimal technical and personnel requirements, will be a stand-out product in the COVID-19 test market.'
Covid-ID Lab was designed to be a rapid, accurate, and robust COVID-19 test system with reduced operating costs and increased convenience and portability. XPhyto expects 3a to receive ISO 13485 medical device manufacturer approval by the end of February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March. Initial commercial manufacturing is planned for Germany, with additional capacity in other jurisdictions to follow. The sales launch in Europe is targeted for April 2021. XPhyto is currently in discussions with potential distribution and wholesale partners in Europe and the Middle East.
XPhyto and 3a are also developing a portfolio of oral biosensor screening tests for detection of bacterial and viral infectious diseases, including influenza A, group A strep, stomatitis, periimplantitis, and periodontitis. Additional pandemic-focused biosensors are in development, specifically for H1N1 (swine flu) and H5N1 (avian flu). The Company is planning the commercial launch of its first biosensor product in the second half of 2021.
The Company will provide further information and updates in due course.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp.:
Hugh Rogers, CEO, and Director
Investor Inquiries:
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com
Media Inquiries:
MC Services AG
Julia Hofmann, Andreas Jungfer
T: +49 89 210 228 0
E: xphyto@mc-services.eu
Forward-looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ('forward-looking statements'). Forward-looking statements are frequently characterized by words such as 'develop,' 'plan,' 'continue,' 'expect,' 'project,' 'intend,' 'believe,' 'anticipate,' 'estimate,' 'potential,' 'propose' and other similar words, or statements that certain events or conditions 'may' or 'will' occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by applicable law.
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
SOURCE: XPhyto Therapeutics Corp.
Get a daily dose of Hawaii Telegraph news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Hawaii Telegraph.
More InformationAn Afghan taxi-driver in Vancouver told one of us a decade ago that this day would come. "We defeated the ...
DES MOINES, Iowa: As the number of Iowa residents who have been vaccinated against Covid rises, the demand has fallen ...
THE HAGUE, Netherlands: Dutch Prime Minister Mark Rutte announced the easing of the country's months-long coronavirus lockdown on Tuesday. A ...
TORONTO, Canada: The province of Ontario, Canada will offer AstraZeneca vaccines to people 40 years and over. This follows a ...
WASHINGTON D.C.: Citing the need to protect U.S. citizens from contracting the Coronavirus, the U.S. State Department said on April ...
NEW YORK, New York: Those who have been inoculated against COVID-19 with the Pfizer vaccine will likely need a third ...
NEW YORK, New York - U.S. stocks tumbled on Friday following news of a new capital gains tax planned by ...
ORLANDO, Florida: April 19 -- Amazon is moving ahead with plans to launch 3,200 satellites to offer Internet services from ...
LONDON, England: Held down by the government's huge jobs subsidies programme, Britain's unemployment rate surprisingly fell for the second month ...
SYDNEY, NSW, Australia - Stocks in Japan took off on Thursday with solid gains also being recorded in Hong Kong ...
WOONSOCKET, Rhode Island: The major American pharmacy chain CVS Health announced this week that it would offer three brands of ...
BANGKOK, Thailand: Thailand is on the brink of putting the finishing touches to one of the largest projects installed atop ...